



#FutureFresenius – Advancing Patient Care

UniCredit Kepler Cheuvreux 23rd German Corporate Conference - Frankfurt

January 15, 2024

Safe Harbor Statement

This presentation contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, the availability of financing and unforeseen impacts of international conflicts.

Fresenius does not undertake any responsibility to update the forward-looking statements contained in this presentation.

1 Company overview

- 2 Strategic update
- 3 Business update Q3/23
- 4 Financial priorities & outlook FY/23
- 5 Attachments

A global leader in healthcare products and services



Group revenue and number of employees are shown excl. FMC

Global trends offer growth opportunities for Fresenius

>10%



Increasing healthcare spend

More than 10% of global GDP will be spent on healthcare in 2030¹



97%

of data produced by hospitals remains unused³

Managing health data

More than 30% of global data is generated by Life Science and Healthcare and only 2% of data produced is retained the following year⁴

Generic drugs

save the US healthcare system⁶



\$338bn

p.a.

Aging Population

In 2020, 1bn people worldwide were >60 years²

+40%

to 1.4bn until 2030



\$23.1bn

Total funding in 2021

Healthcare investments reach record highs

\$23.1bn was raised by biopharma companies worldwide with a surge in venture investment and fundraising⁵

...while the European healthcare system saves⁷

€100bn

p.a.



Sources: ¹ OECD, Health at a Glance (2023), ² WHO, Ageing and health (2022), ³ Deloitte, Health Data (2023), ⁴ Deloitte, Health Data (2023)

⁵ World Economic Forum, Healthcare Outlook (2021), ⁶ AAM report (2021), ⁷ UBS, Longer Term Investments: Generics (2018)

Our purpose for #FutureFresenius – Advancing Patient Care



At the heart of healthcare

30+ studies in parenteral and enteral nutrition

3 multiproduct biologic drug substance facilities

Pipeline of **10+** biosimilars

>160 IV Drug products in portfolio

Breakthrough technology infusion system

Device supplier for 1/3rd of FDA/EMA-approved CAR-T cell therapies

#2 for plasma collection devices globally

Installed base of **>1M** medical pumps

MEDICAL EXPERTISE **MANUFACTURING SCALE** **CLINICAL PRACTICE** **TECHNOLOGY KNOW-HOW**

137 hospitals in Germany & Spain

11,500 physicians active in Germany

24M patients treated every year

>20 surgical robots in practice

~400k anonymized routine treatment data sets

- ✓ **Better Treatments**
- ✓ **Better Outcomes**
- ✓ **Better Care**

#FutureFresenius – Operating Companies and Investment Companies

#FutureFresenius *Advancing Patient Care*

Operating Companies

Profitability optimization and growth



Healthcare products

for critically and chronically ill patients



Healthcare services

along the care continuum

World-class therapies through system-critical healthcare products and services

(Bio)Pharma Platform

MedTech Platform

Care Provision Platform

Investment Companies

Financial value management




Dialysis provision and products




Project business and services

Deconsolidation
effective by December 2023

Therapy-focused platforms – Bringing the future of healthcare to patients



Fresenius Kabi – Accelerating our growth, driving performance



FRESENIUS HELIOS

Healthcare services
along the care continuum



Fresenius Helios – Powerful set of care provision assets



Healthcare products
for critically and chronically ill patients



Leading healthcare services delivering value for >24 million patients yearly



€7.0B



€4.4B

- Continuing **stable margin delivery**
- Increased **focus on return on capital** and **cash flow**
- Clear **strategy** for **value creation** across portfolio
- CMD envisaged for 2Q/2024

ⓧ FY/22 Net Sales; Eugin Group no longer included in this presentation due to divestment – revenue figures thus do not add up to Helios' reported total revenue




Fresenius share & shareholder structure

Share price development LTM (%)




Click to view our interactive share price tool



Analyst recommendations




Click to view downloadable set of the consensus data




Shareholder structure by investors type

Retail holdings **9%**



Shareholder structure by region


Not identified **4%**



Progressive dividend policy

Dividend

Payout ratio¹



Progressive dividend policy

- ✓ Commitment to delivering attractive and predictable shareholder return
- ✓ Dividend for FY/22 remained on prior-year level despite challenging environment
- ✓ Dividend to grow in line with EPS cc growth, but at least stay on prior year level

¹ Based on total dividend paid and group net income before special items

- 1 Company overview
- 2 **Strategic update**
- 3 Business update Q3/23
- 4 Financial priorities & outlook FY/23
- 5 Attachments

#FutureFresenius – ReSet delivered, pacing ReVitalization

Structural simplification


Sharpen focus

Accelerate performance

✓ FMC deconsolidation to be completed by December



✓ Over-delivering on cost savings



✓ Clear ambitions – F³ sets framework

Fresenius Group				
Operating Companies		Investment Companies <i>FSE expectation as major shareholder</i>		
	FRESENIUS KABI	FRESENIUS HELIOS	FRESENIUS MEDICAL CARE	FRESENIUS VAMED
EBIT margin	14 – 17%	9 – 11%	10 – 14%	4 – 6%
Organic revenue growth	4 – 7%	3 – 5%		
CAPITAL EFFICIENCY		CAPITAL STRUCTURE	CASH	DIVIDEND
ROIC 6 – 8%		Leverage ratio 3.0x – 3.5x	Cash Conversion Rate ¹ Around 1	Progressive dividend In line with EPS cc growth but at least on prior year level

✓ Divestment program advancing

Divestments well advancing

Fresenius exits hospital market in Peru ✓

Fresenius sharpens focus and sells fertility services group Eugin ✓

.... ✓

.... ✓

New, more rigorous F³ – Fresenius Financial Framework

Fresenius Group

Operating Companies



14 – 17%

Targeting upper end of range
by 2026



9 – 11%

**EBIT
margin**

**Organic
revenue growth**

4 – 7%

3 – 5%

Investment Companies

FSE expectation as major shareholder



10 – 14%



4 – 6%

CAPITAL EFFICIENCY

ROIC

6 – 8%

CAPITAL STRUCTURE

Leverage ratio

3.0x – 3.5x

CASH

Cash Conversion Rate¹

Around 1


DIVIDEND

Progressive dividend


**In line with EPS cc growth
but at least on prior year level**

¹ Cash Conversion Rate – defined as adjusted FCFBIT / EBIT before special items
All figures before special items

#FutureFresenius – Delivering on our promises; quarter on quarter



#FutureFresenius - REVITALIZE



1 Company overview

2 Strategic update

3 Business update Q3/23

4 Financial priorities & Outlook FY/23

5 Attachments

Q3/23: #FutureFresenius momentum continuing



Kabi and Helios deliver strong performance



Cost savings delivery ahead of schedule



Simplification advanced: FMC deconsolidation effective December



VAMED EBIT positive



Divestment program advancing



#FutureFresenius – 2023 outlook improved


Kabi and Helios: Consistent strong delivery

OPERATING COMPANIES

		Q1/23	Q2/23	Q3/23
 FRESENIUS KABI	REVENUE <small>ORG.</small>	+7% ✓	+8% ✓	+7% ✓
	EBIT	-4% ✓	+5% ✓	+6% ✓

 FRESENIUS HELIOS	REVENUE <small>ORG.</small>	+5% ✓	+7% ✓	+5% ✓
	EBIT	+2% ✓	+3% ✓	+8%


INVESTMENT COMPANY

 FRESENIUS VAMED	REVENUE <small>ORG.</small>	+13%	-7%	+13%
	EBIT	-€27m	-€20m	€10m

✓ *Within or above structural growth/margin band according to Fresenius Financial Framework*

Group EBIT outlook improved for FY/23

Kabi and Helios at top-end of structural growth band



All growth rates in constant currency (cc), before special items

Improving debt profile: A top priority

**MORE
FLEXIBILITY**

**LOWER
EXPENSES**


**HIGHER
EPS**

Key efforts



Cost savings

FY/23 savings target achieved



Organic growth

Top-end of growth band



Operating gains

Operating companies in margin band YTD



**Divestments of
non-core assets**

Divestments advancing; hospital exit in Peru signed

Advancing patient care – strong partnerships, launches and recognition

RECENT HIGHLIGHTS



Fresenius Kabi **signed agreement** with Virginia Oncology Associates to deliver **Ivenix Infusion System**

mAbxience and **Abbott** enter **strategic partnership**

Fresenius Kabi **launches** Tyenne®, the **first approved tocilizumab biosimilar** in the **European Union**

Fresenius Kabi and Lupagen enter into strategic development and supply agreement to bring **cell and gene therapies to the bedside**

Advancing patient care – Fresenius Kabi Named Vizient Supplier Partner of the Year

vizient®

Vizient's members include more than half of all U.S. acute care health systems and 97% of U.S. academic medical centers.

This is their most prestigious supplier award.

“Fresenius Kabi has demonstrated how suppliers can work differently with Vizient to ensure that together we are delivering on our provider customer’s holistic needs relative to cost, quality, and market performance. They have also shown exemplary commitment to quality and service, putting providers and the patients they care for at the center of all they do.” – Vizient



Advancing patient care – delivering quality and innovative healthcare

RECENT HIGHLIGHTS



Opening of the Quirónsalud Valdebebas Medical Center in Madrid with 18 specialties, state-of-the-art facilities and a highly qualified team

Quirónsalud Málaga launches an **Advanced Clinical Research Program** with specific **International Clinical Trials** for cancer patients

Helios ENDO clinic in Hamburg pilots the use of **artificial intelligence** in building automation through **digital twin**

Launch of 3 new apprentice classes in **newly founded Helios Training and Formation Center** in Bad Saarow

Five Quirónsalud hospitals recognized as “World’s Best Specialized Hospitals 2024”


Specialty	Hospital Name
GASTROENTEROLOGY	HOSPITAL UNIVERSITARIO QUIRÓNSALUD MADRID
ORTHOPEDECS	HOSPITAL UNIVERSITARI DEXEUS
ONCOLOGY	CENTRO MÉDICO TEKNON
PEDIATRICS	HOSPITAL RUBER INTERNACIONAL
ONCOLOGY	HOSPITAL UNIVERSITARIO FUNDACIÓN JIMÉNEZ DÍAZ

Selected specialties shown

Q3/23 – Strong Group performance paced by Kabi and Helios



- Start of IFRS 5 application in Q3/23 – FMC only included below EBIT
- Strong revenue growth driven by Operating Companies and Vamed
- EBIT growth reflects strong performance of Operating Companies; Vamed with operational improvement



- Higher interest expense at -€109m (Q3/22: -€67m) due to rising interest rate environment
- Tax rate of 24.1% in Q3; Q1-3/23 at 25.2% in line with FY/23 expectation (25-26%)
- Healthy operating cash flow
- Leverage ratio 15bps below Q2 at 4.03x; above target range of 3.0x to 3.5x


P&L growth rates in constant currency (cc), before special items
 Net income attributable to shareholders of Fresenius SE & Co. KGaA
 Net Debt/EBITDA excluding Fresenius Medical Care

Fresenius Kabi: Strong growth and margin momentum

Q3/23 results



QUARTERLY FINANCIALS



Before special items


MAIN DEVELOPMENTS

- Organic revenue growth of 7% at top-end of structural growth band
- Growth Vectors contributing combined 12% organic revenue growth (MedTech: 8%; Nutrition: 9%; Biopharma: 71%)
- Pharma with robust top-line
- Strong Q3 EBIT margin above 14% with YoY margin expansion in all business units
- EBIT improvement driven by operational leverage and excellent progress on cost and efficiency measures ahead of plan

Fresenius Helios: Usual summer effect but strong YoY improvement Q3/23 results



QUARTERLY FINANCIALS



Before special items

MAIN DEVELOPMENTS


- Consistent strong organic revenue growth YTD at top-end of structural growth band
- Performance at Helios Germany driven by solid activity levels and favorable patient mix; Helios Spain with continued healthy activity levels despite seasonal effects
- Strong 8% YoY EBIT growth and nice YoY improvement in EBIT margin – supported by cost savings progress and government relief funds
- Fertility with strong improvement YoY driven by price and mix effects

Fresenius Vamed: Back to positive operating performance

Q3/23 results



QUARTERLY FINANCIALS



Before special items

TRANSFORMATION UPDATE


- Revenue growth in Q3 driven by both Service as well as Project business
- Turnaround in EBIT led by High-End Services and Health Facility Operations
- Restructuring measures underway, clear implementation roadmap to ensure sustainable operational turnaround
- Special items of €109m booked in Q3/23 (YTD: €441m); predominantly non-cash
- Positive operating earnings expected in Q4/23
- Target to be back in structural EBIT margin band of 4% to 6% by 2025

Cost savings program delivering more quickly than forecasted

PLANNED UNTIL 2025

Cost savings | EBIT view


☐ Thereof FMC



One-time Costs

~€700-750m between 2023-2025, thereof 1/3 FSE

FOCUS ON 2023



2/3 of FSE costs expected to occur in 2023

✓ ~€430m delivered in Q1-3

✓ ~€200m delivered in Q1-3

- Focus on Fresenius Group excl. FMC
- Cost savings program is delivering on 2023 targets and beyond
- FY/23 EBIT savings target already achieved in Q1-3
- Kabi as largest contributor to cost savings
- Only ~€90m of one-time costs spent in Q1-3
- Focus on achieving the full €350m savings by FY/25

Operating cash flow drives Q3/23

€m	Q3/23	Q3/22	Q3/23 LTM	Q3/22 LTM
OCF - continuing operations	648	598	2,084	1,886
% OCF Margin	11.7%	11.1%	9.3%	8.9%
Capex	-272	-223	-1,126	-1,091
Capex in % of revenue	-4.9%	-4.1%	-5.1%	-5.1%
Acquisitions	-181	-484	-237	-770
Dividends	1	--	-445	-275
Lease liabilities	-75	-46	-233	-150
FCF	121	-155	43	-400

- Q3 OCF from continuing operations (excl. FMC) increased by 8% over prior-year quarter
- Kabi: strong OCF development driven by operating performance and improved Working Capital management
- Helios: impacted by higher working capital and phasing effects in H2/22
- LTM OCF Margin at a healthy 9.3%
- CAPEX in line with FY/23 expectation of around 5%

- 1 Company overview
- 2 Strategic update
- 3 Business update Q3/23

4 Financial priorities & outlook

- 5 Attachments

Strong balance sheet is a key pillar of #FutureFresenius: Debt reduction a priority for 2024 and beyond



Stringent capital allocation and focus on cash flow are key



Improved credit outlook by Fitch is strong testament to successful execution of #FutureFresenius



Clear commitment to Investment Grade rating and 3.0x to 3.5x leverage range




Refinancing of 2024 maturities concluded



Conservative fix/floating mix of ~85%/15%

¹ Promissory note loans

CREDIT RATINGS

Standard & Poor's	BBB	Outlook: negative
Fitch	BBB-	Outlook: stable 
Moody's	Baa3	Outlook: stable

REFINANCING ACTIVITIES FOR MAJOR 2024 MATURITIES CONCLUDED



Schuldschein Loan¹

- May 2023
- **€850m**
- 3, 5 and 7 years maturities
- ESG-linked



CHF Bond

- October 2023
- **CHF275m**
- 5 years maturity
- Debut bond in CHF



Euro Bond

- October 2023
- **€500m**
- 7 years maturity

Outlook for FY/23 improved

Fresenius Group

Revenue growth excluding FMC (organic):
Mid-single-digit growth

EBIT (cc growth) excluding FMC:
Broadly flat development
(Previously: Broadly flat-to-mid-single-digit decline)

Operating Companies



- **Mid-single-digit** organic revenue growth
- **Around 14%;** structural EBIT margin band of **14 – 17%**



- **Mid-single-digit** organic revenue growth
- **Within** structural EBIT margin band of **9 – 11%**

Investment Companies



- **With adoption of IFRS 5 outlook is provided ex FMC**
- **Performance of FMC reflected in FSE's P&L below EBIT**



- **Low-to-mid-single-digit** organic revenue growth
- **Clearly below** structural EBIT margin band of **4 – 6%**

FMC: Accounting effects in Q3/23 due to IFRS 5 application

2023

JULY 14: EGM

- **Change of legal form approved** by shareholders of FMC
- Trigger for IFRS 5 accounting and initial **impairment test**
- **No P&L valuation effect** due to FMC's market capitalization being above consolidated shareholders' equity of FMC

SEP. 30: Q3

- Subsequent measurement under **IFRS 5**
- P&L valuation effect of ~€2 bn given FMC's market capitalization below consolidated shareholders equity of FMC
- **Thereof -€0.6 bn** attributable to **shareholders of Fresenius SE**
- **Cash-neutral** and reported as a **special item**

REGISTRATION OF LEGAL FORM IN COMMERCIAL REGISTER

- Expected to be effective by December 2023
- At equity accounting under IAS 28 starts
- Likely leading to **one-time non-cash P&L effect** due to deconsolidation

AT EQUITY ACCOUNTING

- Ongoing **at equity accounting** under IAS 28 for FMC
- Separate line for at equity result in P&L

2023 Targets for Environment, Social, Governance (ESG) KPIs

Targets aligned with Management Board Compensation Short-term Incentive (STI) 2023

Quality / Patients



Net Promoter Score

Net Promoter Score (NPS) is a KPI that ensures that FMC maintains excellent patient relationships and uses the patients' voice to gain strategic insights

Target Value: 70

Quality / Patients



Audit & Inspection Score

Critical and major observations from regulatory authority's GMP inspections and major nonconformities in TÜV ISO 9001 audits in relation to the number of inspections/audits

Target: 2.3

Quality / Patients



Inpatient Quality Indicator

Number of quality indicators achieved compared to the total number of indicators; individual target setting and measurement of achievement in Helios segments Germany and Spain

Target Germany: 88%
Target Spain: 55%

Quality / Patients



Patient Satisfaction

Degree of patient satisfaction in Vamed health care facilities and the patient's satisfaction with the overall services provided in VAMED health care facilities.

Target: 1.7

Employee Engagement Index



Employee Engagement Index (EEI) describes how positively employees associate themselves with the employer, how committed they feel and how engaged they are at work.

Target: 4.33

Attachments

FY/23 – Other financial KPIs for Fresenius Group

With adoption of IFRS 5 – Guidance to be provided ex FMC only:

Q1-3/23 (ex FMC)		
Profitability	Interest expense	€300m
	Tax rate	25.2%
Capital Allocation	CAPEX	4.4%
	CCR LTM	0.9
	ROIC	5.0%
	Leverage ratio	4.03x

Around the middle of the €400 to €440m range

Between 25 to 26%

Around 5%


Below 1

Around 5%


Below 4x

Capital efficiency and returns


ROIC



CCR¹



NET DEBT/EBITDA²



- Excluding FMC ROIC around 40 bps higher
- Q3/2023 ROIC still below 6-8% target corridor
- FY/23 is inflection point

- Q3/23: CCR stable at 0.9x (excl. FMC)
- YoY improvement from 0.7x in Q3/22 to 0.9x in Q3/23
- Increased focus on cash and cash return in the Group


- Strong commitment to 3.0 to 3.5x leverage corridor and investment grade rating
- Sequential improvement by 16 bps
- Excluding potential divestments

¹ LTM


² At LTM average exchange rates for both net debt and EBITDA; pro forma closed acquisitions/divestitures; before special items; after effects from assets held for sale at FMC

Fresenius Group: Revenue Q1-Q3/23

Revenue by Region



Revenue by Business Segment



Revenue Q1-3/2023

Fresenius Kabi: Q3/23 & Q1-3/23 Organic Revenue Growth by Product Group

€m	Q3/23	Δ YoY organic	Q1-3/23	Δ YoY organic
<i>MedTech</i>	369	8%	1,113	9%
<i>Nutrition</i>	587	9%	1,803	10%
<i>Biopharma</i>	111	71%	264	59%
Growth Vectors¹	1,067	12%	3,180	11%
Pharma (IV Drugs & Fluids)	941	1%	2,833	3%
Corporate	13	--	0	--
Total revenue	2,021	7%	6,013	7%

¹ consists of MedTech, Nutrition, Biopharma

Fresenius Kabi: Q3/23 & Q1-3/23 EBIT(DA) development

€m	Q3/23	Δ YoY cc	Q1-3/23	Δ YoY cc
Total EBITDA Margin	406 20.1%	6% +90 bps	1,209 20.1%	4% -10 bps
Growth Vectors ¹ Margin	104 9.8%	25% +180 bps	288 9.1%	+4% -30 bps
Pharma (IV Drugs & Fluids) Margin	200 21.3%	9% +150 bps	603 21.3%	7% +90 bps
Corporate	-15	--	-28	--
Total EBIT Margin	289 14.3%	6% +80 bps	863 14.4%	2% -10 bps

All figures before special items

Margin growth at actual rates

¹ consists of MedTech, Nutrition, Biopharma

For a detailed overview of special items and adjustments please see the reconciliation tables provided on our website <https://www.fresenius.com/financial-results>.

Fresenius Helios: Q3/23 & Q1-3/23 Key Financials

€m	Q3/23	Δ YoY cc	Q1-3/23	Δ YoY cc
Total revenue	2,953	5%¹	9,132	6%¹
Thereof Helios Germany	1,800	4% ¹	5,451	3% ¹
Thereof Helios Spain	1,088	5% ¹	3,481	9% ¹
Thereof Helios Fertility	64	13% ¹	198	13% ¹
Total EBIT	239	8%	861	4%
Margin	8.1%	+30 bps	9.4%	-20 bps
Thereof Helios Germany Margin	157 8.7%	11% +60 bps	466 8.5%	4% 0 bps
Thereof Helios Spain Margin	81 7.4%	-2% -60 bps	392 11.3%	3% -60 bps
Thereof Helios Fertility Margin	5 7.8%	50% +130 bps	16 8.1%	13% -10 bps
Thereof Corporate	-4	33%	-13	24%

¹ Organic growth

All figures before special items

For a detailed overview of special items and adjustments please see the reconciliation tables provided on our website <https://www.fresenius.com/financial-results>.

Fresenius Helios: Key Metrics

	Q1-3/23	FY/22	Δ
Helios Germany			
Hospitals	86	87	-1%
- Acute care hospitals	83	84	-1%
Beds	29,993	30,352	-1%
- Acute care hospitals	29,427	29,786	-1%
Admissions	4,143,525	5,508,158	
- patients treated in hospital	854,118	1,084,676	
- patients treated as outpatient	3,289,407	4,423,482	
Helios Spain (incl. Latin America)			
Hospitals	58	58	0%
Beds	8,267	8,259	0%
Admissions (including outpatients)	15,466,307	18,853,264	
- patients treated in hospital	850,578	1,067,410	
- patients treated as outpatient	14,615,729	17,785,854	

Fresenius Vamed: Q3/23 & Q1-3/23 Key Financials

€m	Q3/23	Δ YoY cc	Q1-3/23	Δ YoY cc
Total revenue	647	+13%	1,761	7%
Thereof organic revenue		+13%		6%
Project business	191	24%	426	5%
Service business	456	9%	1,335	7%
Total EBIT¹	10	0%	-37	--
Order intake ²	40	-74%	262	-61%
Order backlog ²			2,908 ³	-22% ⁴

¹ Before special items

² Project business only

³ Thereof conditionally agreed order backlog €839 million

⁴ Versus December 31, 2022

Fresenius Group: Calculation of Noncontrolling Interests

€m	Q1-3/23	Q1-3/22
Earnings before tax and noncontrolling interests	1,328	1,470
Taxes	-334	-326
Noncontrolling interests, thereof	-46	-72
Fresenius Kabi	-47	-52
Fresenius Helios	-14	-14
Fresenius Vamed	-2	-3
Fresenius Vamed's 23% external ownership	17	-3
Net income from operations to be deconsolidated	160	212
Net income attributable to Fresenius SE & Co. KGaA	1,108	1,284

Before special items

For a detailed overview of special items and adjustments please see the reconciliation tables provided on our website <https://www.fresenius.com/financial-results>.





Fresenius Group: Cash Flow

€m	Q3/23	Q3/23 LTM	LTM Margin	Q3 Δ YoY
Operating Cash Flow – continuing operations	648	2,084	9.3%	8%
Capex (net)	-272	-1,126	-5.0%	22%
Free Cash Flow – continuing operations	376	958	4.3%	0%
(before acquisitions, dividends and lease liabilities)				
Acquisitions (net)	-181	-237		
Dividends	1	-445		
Lease liabilities	-75	-233		
Free Cash Flow – continuing operations	121	43	0.2%	--
(after acquisitions, dividends and lease liabilities)				

Fresenius Group: Reconciliation adjusted Free Cash Flow for CCR





€m	Q3/23	Q3/22	Q1-3/23 LTM	Q1-3/22 LTM
Operating Cash Flow	648	598	2,084	1,886
Capex (net)	-272	-223	-1,126	-1,092
Free Cash Flow	376	375	958	794
(before acquisitions and dividends)				
Special items (net income before minorities)	+35	+53	+245	+141
Interests (before special items)	+109	+67	+380	+215
Taxes (before special items)	+99	+93	+445	+481
Adjusted Free Cash Flow for CCR	619	588	2,028	1,631

Cash Flow development Q3/23

€m	Operating Cash Flow				Capex (net)				Free Cash Flow ¹			
	Q3/23	Q3/22	Q3/23 Margin	Q3/22 Margin	Q3/23	Q3/22	Q3/23 Margin	Q3/22 Margin	Q3/23	Q3/22	Q3/23 Margin	Q3/22 Margin
 FRESENIUS KABI	380	301	18.8%	14.5%	-110	-118	-5.4%	-5.7%	270	183	13.4%	8.8%
 FRESENIUS HELIOS	208	353	7.0%	12.5%	-143	-90	-4.8%	-3.2%	65	263	2.2%	9.3%
 FRESENIUS VAMED	50	-18	7.7%	-3.1%	-18	-10	-2.8%	-1.8%	32	-28	4.9%	-4.9%
Corporate/Other	10	-38	--	--	-1	-5	--	--	9	-43	--	--
 FRESENIUS	648	598	11.7%	11.1%	-272	-223	-4.9%	-4.1%	376	375	6.8%	7.0%
Operations to be deconsolidated (FMC)	760	658	15.4%	12.9%	-134	-157	-2.7%	-3.1%	626	501	12.7%	9.8%

¹ Before acquisitions, dividends and lease liabilities

Cash Flow development Q3/23 LTM

€m	Operating Cash Flow				Capex (net)				Free Cash Flow ¹			
	Q3/23 LTM	Q3/22 LTM	Q3/23 Margin	Q3/22 Margin	Q3/23 LTM	Q3/22 LTM	Q3/23 Margin	Q3/22 Margin	Q3/23 LTM	Q3/22 LTM	Q3/23 Margin	Q3/22 Margin
 FRESENIUS KABI	879	878	10.9%	11.5%	-472	-492	-5.8%	-6.4%	407	386	5.1%	5.1%
 FRESENIUS HELIOS	1,333	1,020	11.0%	8.8%	-590	-553	-4.9%	-4.8%	743	467	6.1%	4.0%
 FRESENIUS VAMED	-4	72	-0.2%	3.0%	-28	-50	-1.1%	-2.1%	-32	22	-1.3%	0.9%
Corporate/Other	-124	-84	--	--	-36	4	--	--	-160	-80	--	--
 FRESENIUS ²	2,084	1,886	9.3%	8.9%	-1,126	-1,091	-5.0%	-5.2%	958	795	4.3%	3.7%
Operations to be deconsolidated (FMC)	2,509	2,237	17.3%	11.7%	-632	-755	-4.4%	-3.9%	1,877	1,482	12.9%	7.8%

¹ Before acquisitions, dividends and lease liabilities

² Including FMC dividends

Revenue by Business Segment – FX, Acquisitions/Divestitures Effects Q3/23

€m	Q3/23	Q3/22	Growth at actual rates	Currency translation effects	Growth at constant rates	Organic growth	Acquisitions	Divestitures/Others
Fresenius Kabi	2,021	2,071	-2%	-9%	7%	7%	1%	-1%
Fresenius Helios	2,953	2,829	4%	-1%	5%	5%	0%	0%
Fresenius Vamed	647	572	13%	0%	13%	13%	0%	0%
Total	5,518	5,386	2%	-4%	6%	6%	0%	0%

Revenue by Business Segment – FX, Acquisitions/Divestitures Effects Q1-3/23

€m	Q1-3/23	Q1-3/22	Growth at actual rates	Currency translation effects	Growth at constant rates	Organic growth	Acquisitions	Divestitures/Others
Fresenius Kabi	6,013	5,814	3%	-5%	8%	7%	2%	-1%
Fresenius Helios	9,132	8,685	5%	-1%	6%	6%	0%	0%
Fresenius Vamed	1,761	1,647	7%	0%	7%	6%	1%	0%
Total	16,621	15,862	5%	-2%	7%	6%	1%	0%

Financial Calendar / Contact

Financial Calendar

21 February 2024	Results FY/23
08 May 2024	Results Q1/24
17 May 2024	Annual General Meeting
31 July 2024	Results Q2/24
06 November 2024	Results Q3/24

Please note that these dates could be subject to change.

Contact

Investor Relations
Fresenius SE & Co. KGaA
phone: +49 6172 608-2485
e-mail: ir-fre@fresenius.com

Social Media

Follow Fresenius Investor Relations on LinkedIn:



For further information and current news: www.fresenius.com



www.twitter.com/fresenius_ir



www.linkedin.com/company/fresenius-investor-relations



#FutureFresenius